Project description:Background: Infections following prostate biopsy can be associated with significant morbidity and occasional mortality. Studies have suggested an increased incidence in post-biopsy sepsis. The purpose of this study was to determine the effect of a bacteria sensitivity adapted antimicrobial prophylactic strategy on the incidence of sepsis post prostate biopsy.Methods: In October 2008, based on the prevalence of ciprofloxacin-resistant E.coli in the region, our institution modified the prophylactic regimen for prostate biopsy from oral ciprofloxacin alone to a combination of single-dose ciprofloxacin and trimethoprim/sulfamethoxazole. If patients had a history of urosepsis, bacterial prostatitis, organ transplant, or fluoroquinolone use in the preceding 12 months, intramuscular ceftriaxone was administered for prophylaxis. Patients with penicillin allergy received gentamicin. We determined the incidence of ciprofloxacin-resistant bacteremia 16 months before and 16 months after the change in antibiotic protocol.Results: Between June 2007 and September 2008, 9 of 847 (1.06%) patients were admitted with prostate biopsy induced bacteremia secondary to ciprofloxacin-resistant E. coli. In the 16 months following introduction of the described prophylactic regimen, 1 of 989 (0.10%) patients suffered ciprofloxacin-resistant sepsis. The absolute reduction in E. coli sepsis was 0.96% (95%CI 0.2% to 1.7%; p=0.007). The number needed to treat is 104.Conclusions: Bacterial susceptibility to antimicrobial agents is in evolution. Using a regional bacteria sensitivity based approach to biopsy prophylaxis, we have significantly decreased ciprofloxacin-resistant E. coli sepsis in our patients. Regional bacteria sensitivity based protocols may decrease the incidence at other centers and warrants further study.
Project description:American Neurological Association Annual Meeting, Chicago, IL, USA, 27-29 September 2015 The American Neurological Association (ANA) held its annual meeting in Chicago, IL, USA on 27-29 September 2015. The Scientific Programming Advisory Committee was chaired by Dr. S Pleasure from the University of California-San Francisco (CA, USA). The Neuro-Oncology session, chaired by Dr. A Pruitt from the University of Pennsylvania (PA, USA) and cochaired by Dr. J Laterra from Johns Hopkins University (MD, USA), was held on 27 September 2015. Speakers included Dr. D Wainwright (Northwestern University, IL, USA), Dr. N Kolb (University of Utah, UT, USA), Dr. A Nath (NINDS/NIH, MD, USA), Dr. D Franz (Cincinnati Children's Hospital, OH, USA) and Dr. R Lukas (University of Chicago, IL, USA). A summary of key presentations from the Neuro-Oncology section of the 2015 American Neurological Association annual meeting is reported. Preclinical and clinical advances in the use of immunotherapies for the treatment of primary and metastatic CNS tumors are covered. Particular attention is paid to the enzyme indoleamine dioxygenase and the immune checkpoints CTLA4 and PD1 and their ligands. Specific nervous system toxicities associated with novel immunotherapies are also discussed. The recent success of targeting the mTOR pathway in the neurocutaneous syndrome tuberous sclerosis is detailed. Finally, important early steps in our understanding of the common toxicity of chemotherapy induced neuropathy are reviewed.